Wave Life Sciences Ltd. reported $111M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $111M (to Q2 2024). Net income: −$202M, trailing twelve months to Q2 2026. Free cash flow: −$193M, trailing twelve months to Q2 2026. EPS: −$1.08, trailing twelve months to Q2 2026.

WVEWave Life Sciences Ltd.

Healthcare

$3.47-50% 1Y

$3.47

$3.4752 weeks$21.31

WVE as reported

Wave Life Sciences Ltd. reported $111M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$111M

Revenue, trailing twelve months · to Q2 2024 · every figure below is as filed, with no scoring applied

Net income: −$202M
Net income · +56% year on year · trailing twelve months to Q2 2026
Free cash flow: −$193M
Free cash flow · −3.5% year on year · trailing twelve months to Q2 2026
EPS: −$1.08
EPS · +35% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for WVE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$111M	n/a	Q2 2024 · 8 quarters behind
Net income	−$202M	+56%	Q2 2026
EPS	−$1.08	+35%	Q2 2026
Operating margin	−127%	n/a	Q2 2024 · 8 quarters behind
Net margin	−115%	n/a	Q2 2024 · 8 quarters behind
ROE	−54%	n/a	Q2 2026
ROA	−38%	n/a	Q2 2026
Free cash flow	−$193M	−3.5%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.